Influenza virus vaccine (Optaflu, Flucelvax) - Seqirus

Drug Profile

Influenza virus vaccine (Optaflu, Flucelvax) - Seqirus

Alternative Names: Flucelvax; Flucelvax Pediatric; Flucelvax Quadrivalent; Influenza vaccine (Flucelvax); Influenza vaccine (prepared in cell culture) - Seqirus; Optaflu; TIVc

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Seqirus
  • Class Influenza virus vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 23 May 2016 Registered for Influenza virus infections (In adults, In adolescents, In children, Prevention) in USA (IM) ,
  • 09 Nov 2015 CSL’s influenza vaccine business started operating under the brand name Seqirus
  • 23 Mar 2015 The vaccine is approved in the European Union, Iceland and Norway for Influenza virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top